The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial

• DOI: 10.1371/journal.pmed.1000321
• Publication Date: 2010-08-10T19:57:50Z
• Authors: Rajesh T. Gandhi; Lu Zheng; Ronald J. Bosch; Ellen S. Chan; David M. Margolis; Sarah Read; Beatrice Kallungal; Sarah Palmer; Kathy Medvik; Michael M. Lederman; Nadia Alatrakchi; Jeffrey M. Jacobson; Ann Wiegand; Mary Kearney; John M. Coffin; John W. Mellors; Joseph J. Eron
• Keywords: Male; Anti-HIV Agents; viral infections; 610; HIV Infections; infectious diseases; 03 medical and health sciences; Double-Blind Method; Antiretroviral Therapy, Highly Active; Raltegravir Potassium; 616; Humans; Viremia; 0303 health sciences; Cross-Over Studies; R; HIV infection and AIDS; Middle Aged; Viral Load; Pyrrolidinones; 3. Good health; HIV-1; Medicine; Female; Research Article

Most HIV-1-infected patients on effective antiretroviral therapy (ART) with plasma HIV-1 RNA levels below the detection limits of commercial assays have residual viremia measurable by more sensitive methods. We assessed whether adding raltegravir lowered the level of residual viremia in such patients.